News

November 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Philadelphia, PA, November 07, 2022 — Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer...

 

Read More

March 28, 2022

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London

Cheyney, PA, March 28, 2022 — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new preclinical data on its NAV-001...

 

Read More

November 30, 2021

Navrogen Announces Publication of its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers

Navrogen announced today the publication of preclinical data regarding application of its proprietary Block-Removed Immunoglobulin Technology (BRITE) to enhance the efficacy of the CD20-targeting rituximab antibody in the presence...

 

Read More

September 13, 2021

Navrogen Enters into CRADA with USAMRIID to Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID)....

 

Read More

August 17, 2021

Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents

Navrogen and Tavotek will collaborate on the development of future Tavotek oncology assets while utilizing Navrogen’s proprietary screening technology to identify mAb leads that are susceptible to Humoral Immuno-Oncology...

 

Read More

August 9, 2021

Navrogen Closes $3.0M Seed Financing to Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers and Immune-Related Disorders

Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical...

 

Read More

July 1, 2021

Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed Cancers

Navrogen has signed a commercial evaluation license agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for the commercialization of tumor targeted therapies to...

 

Read More

January 11, 2021

Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors

Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of...

 

Read More

September 29, 2020

Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has signed a license agreement with the National Cancer Institute (NCI)...

 

Read More

September 14, 2020

Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic Effects

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to...

 

Read More